Long noncoding RNA FEZF1‐AS1 predicts poor prognosis and modulates pancreatic cancer cell proliferation and invasion through miR‐142/HIF‐1α and miR‐133a/EGFR upon hypoxia/normoxia

Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment‐resistant phenotype induced by the extent of hypoxic stress within the tumor tissue. According to previous studies, miR‐142/HIF‐1α and miR‐133a/EGFR could modulate PC cell proliferation under...

Full description

Saved in:
Bibliographic Details
Published inJournal of cellular physiology Vol. 234; no. 9; pp. 15407 - 15419
Main Authors Ou, Zheng‐Lin, Zhang, Min, Ji, Lian‐Dong, Luo, Zhen, Han, Tong, Lu, Ye‐Bin, Li, Yi‐Xiong
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.09.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment‐resistant phenotype induced by the extent of hypoxic stress within the tumor tissue. According to previous studies, miR‐142/HIF‐1α and miR‐133a/EGFR could modulate PC cell proliferation under hypoxic and normoxic conditions, respectively. In the present study, FEZF1‐AS1, a recently described oncogenic long noncoding RNA, was predicted to target both miR‐142 and miR‐133a; thus, we hypothesized that FEZF1‐AS1 might affect PC cell proliferation through these two axes under hypoxic or normoxic conditions. In PC cell lines, FEZF1‐AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR‐142/HIF‐1α axis under hypoxic condition; however, FEZF1‐AS1 failed to affect the protein levels of HIF‐1α and VEGF under the normoxic condition, suggesting the existence of another signaling pathway under normoxic condition. As predicted by an online tool, FEZF1‐AS1 could target miR‐133a to inhibit its expression; under the normoxic condition, FEZF1‐AS1 exerted its effect on PC cell lines through miR‐133a/EGFR axis. Taken together, FEZF1‐AS1 might be a promising target in controlling the aberrant proliferation and invasion of PC cell lines. FEZF1‐AS1 could promote pancreatic cancer (PC) cell proliferation and invasion through miR‐142/HIF1A axis under hypoxic condition while through miR‐133a/EGFR axis under normoxic condition. FEZF1‐AS1 might be a promising target in controlling the proliferation and proliferation of PC cell lines.
AbstractList Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment-resistant phenotype induced by the extent of hypoxic stress within the tumor tissue. According to previous studies, miR-142/HIF-1α and miR-133a/EGFR could modulate PC cell proliferation under hypoxic and normoxic conditions, respectively. In the present study, FEZF1-AS1, a recently described oncogenic long noncoding RNA, was predicted to target both miR-142 and miR-133a; thus, we hypothesized that FEZF1-AS1 might affect PC cell proliferation through these two axes under hypoxic or normoxic conditions. In PC cell lines, FEZF1-AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR-142/HIF-1α axis under hypoxic condition; however, FEZF1-AS1 failed to affect the protein levels of HIF-1α and VEGF under the normoxic condition, suggesting the existence of another signaling pathway under normoxic condition. As predicted by an online tool, FEZF1-AS1 could target miR-133a to inhibit its expression; under the normoxic condition, FEZF1-AS1 exerted its effect on PC cell lines through miR-133a/EGFR axis. Taken together, FEZF1-AS1 might be a promising target in controlling the aberrant proliferation and invasion of PC cell lines.
Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment‐resistant phenotype induced by the extent of hypoxic stress within the tumor tissue. According to previous studies, miR‐142/HIF‐1α and miR‐133a/EGFR could modulate PC cell proliferation under hypoxic and normoxic conditions, respectively. In the present study, FEZF1‐AS1, a recently described oncogenic long noncoding RNA, was predicted to target both miR‐142 and miR‐133a; thus, we hypothesized that FEZF1‐AS1 might affect PC cell proliferation through these two axes under hypoxic or normoxic conditions. In PC cell lines, FEZF1‐AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR‐142/HIF‐1α axis under hypoxic condition; however, FEZF1‐AS1 failed to affect the protein levels of HIF‐1α and VEGF under the normoxic condition, suggesting the existence of another signaling pathway under normoxic condition. As predicted by an online tool, FEZF1‐AS1 could target miR‐133a to inhibit its expression; under the normoxic condition, FEZF1‐AS1 exerted its effect on PC cell lines through miR‐133a/EGFR axis. Taken together, FEZF1‐AS1 might be a promising target in controlling the aberrant proliferation and invasion of PC cell lines. FEZF1‐AS1 could promote pancreatic cancer (PC) cell proliferation and invasion through miR‐142/HIF1A axis under hypoxic condition while through miR‐133a/EGFR axis under normoxic condition. FEZF1‐AS1 might be a promising target in controlling the proliferation and proliferation of PC cell lines.
Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment-resistant phenotype induced by the extent of hypoxic stress within the tumor tissue. According to previous studies, miR-142/HIF-1α and miR-133a/EGFR could modulate PC cell proliferation under hypoxic and normoxic conditions, respectively. In the present study, FEZF1-AS1, a recently described oncogenic long noncoding RNA, was predicted to target both miR-142 and miR-133a; thus, we hypothesized that FEZF1-AS1 might affect PC cell proliferation through these two axes under hypoxic or normoxic conditions. In PC cell lines, FEZF1-AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR-142/HIF-1α axis under hypoxic condition; however, FEZF1-AS1 failed to affect the protein levels of HIF-1α and VEGF under the normoxic condition, suggesting the existence of another signaling pathway under normoxic condition. As predicted by an online tool, FEZF1-AS1 could target miR-133a to inhibit its expression; under the normoxic condition, FEZF1-AS1 exerted its effect on PC cell lines through miR-133a/EGFR axis. Taken together, FEZF1-AS1 might be a promising target in controlling the aberrant proliferation and invasion of PC cell lines.Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment-resistant phenotype induced by the extent of hypoxic stress within the tumor tissue. According to previous studies, miR-142/HIF-1α and miR-133a/EGFR could modulate PC cell proliferation under hypoxic and normoxic conditions, respectively. In the present study, FEZF1-AS1, a recently described oncogenic long noncoding RNA, was predicted to target both miR-142 and miR-133a; thus, we hypothesized that FEZF1-AS1 might affect PC cell proliferation through these two axes under hypoxic or normoxic conditions. In PC cell lines, FEZF1-AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR-142/HIF-1α axis under hypoxic condition; however, FEZF1-AS1 failed to affect the protein levels of HIF-1α and VEGF under the normoxic condition, suggesting the existence of another signaling pathway under normoxic condition. As predicted by an online tool, FEZF1-AS1 could target miR-133a to inhibit its expression; under the normoxic condition, FEZF1-AS1 exerted its effect on PC cell lines through miR-133a/EGFR axis. Taken together, FEZF1-AS1 might be a promising target in controlling the aberrant proliferation and invasion of PC cell lines.
Author Luo, Zhen
Li, Yi‐Xiong
Lu, Ye‐Bin
Han, Tong
Ou, Zheng‐Lin
Ji, Lian‐Dong
Zhang, Min
Author_xml – sequence: 1
  givenname: Zheng‐Lin
  surname: Ou
  fullname: Ou, Zheng‐Lin
  organization: Xiangya Hospital, Central South University
– sequence: 2
  givenname: Min
  surname: Zhang
  fullname: Zhang, Min
  organization: The Second Xiangya Hospital, Central South University
– sequence: 3
  givenname: Lian‐Dong
  surname: Ji
  fullname: Ji, Lian‐Dong
  organization: Xiangya Hospital, Central South University
– sequence: 4
  givenname: Zhen
  orcidid: 0000-0003-2444-5138
  surname: Luo
  fullname: Luo, Zhen
  organization: The Third Xiangya Hospital, Central South University
– sequence: 5
  givenname: Tong
  surname: Han
  fullname: Han, Tong
  organization: The Second Xiangya Hospital, Central South University
– sequence: 6
  givenname: Ye‐Bin
  surname: Lu
  fullname: Lu, Ye‐Bin
  organization: Xiangya Hospital, Central South University
– sequence: 7
  givenname: Yi‐Xiong
  surname: Li
  fullname: Li, Yi‐Xiong
  email: liyixiong2011@hotmail.com
  organization: Xiangya Hospital, Central South University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30693518$$D View this record in MEDLINE/PubMed
BookMark eNp1kc9uEzEQxi1URNPCgRdAK3GBwzb-txv7GEXZtigCFODCxXIcO3G0a2_tXSA3HoFX4c4z8BA8Cd4kvVRw8ozn9332zFyAM-edBuA5glcIQjzeqfYKM8TYIzBCkE9yWhb4DIxSDeW8oOgcXMS4gxByTsgTcE5gyUmB2Aj8Wni3yZKf8mubouXbaVbNP1foz_cf0w8oa4NeW9XFrPU-pMxvnI82ZtKts8av-1p2OhWlU0HLzqpMpVCHTOm6HvDaGh1SwbuDxLovMg5Jtw2-32yzxi7TS4ji8c1tNUS_fx69j_eEyPH8ulpmfZtE233rv1k5dj40Q_AUPDayjvrZ6bwEn6r5x9lNvnh3fTubLnKFS8ZyWmBaQINKpCQxrFytkGbJuZhISBTSVGPDy4nhZMKxKYgxWpaI8QKVkK6gIZfg1dE3NXTX69iJxsahQ-m076PAaMIpLSEhCX35AN35Prj0O4Ex5oyyNPZEvThR_arRa9EG28iwF_d7ScD4CKjgYwzaCGW7wxi7IG0tEBTD5kXavDhsPileP1Dcm_6LPbl_tbXe_x8Ub2bvj4q_LOLA1A
CitedBy_id crossref_primary_10_2147_NSS_S385755
crossref_primary_10_2147_OTT_S235970
crossref_primary_10_1186_s12935_021_02125_1
crossref_primary_10_1016_j_canlet_2020_11_007
crossref_primary_10_1016_j_jare_2025_02_001
crossref_primary_10_3390_cancers15133486
crossref_primary_10_1016_j_prp_2019_152687
crossref_primary_10_1186_s13045_020_01030_w
crossref_primary_10_1016_j_ejphar_2023_175535
crossref_primary_10_1089_dna_2024_0184
crossref_primary_10_1186_s12935_020_01370_0
crossref_primary_10_1007_s00018_019_03444_3
crossref_primary_10_1186_s12929_020_00654_x
crossref_primary_10_1007_s11033_023_08370_z
crossref_primary_10_1007_s11033_024_09802_0
crossref_primary_10_3390_ncrna6030027
crossref_primary_10_1016_j_prp_2023_154438
crossref_primary_10_2174_1566524022666220120123557
crossref_primary_10_3389_fonc_2021_765216
crossref_primary_10_3390_ijms22147261
crossref_primary_10_32604_or_2022_03553
crossref_primary_10_1111_cas_15388
crossref_primary_10_3390_cells9112353
crossref_primary_10_1016_j_bj_2021_03_005
crossref_primary_10_2147_OTT_S261461
crossref_primary_10_18632_aging_202960
crossref_primary_10_1007_s12672_022_00522_0
crossref_primary_10_1042_BSR20190754
Cites_doi 10.3892/mmr.2015.3144
10.1038/onc.2015.325
10.1089/ars.2007.1628
10.18632/oncotarget.8834
10.1002/jcb.25988
10.2478/s11658-014-0212-6
10.1016/j.bbrc.2011.04.035
10.3892/ol.2013.1620
10.1093/ije/dyx232
10.1007/978-1-4939-3378-5_21
10.1016/j.cell.2011.07.014
10.1016/j.biopha.2017.08.057
10.1177/1535370214555665
10.1007/s11010-013-1795-3
10.1586/17474124.2016.1117386
10.1016/S0360-3016(00)00803-8
10.1242/bio.021774
10.1016/j.ctrv.2017.08.007
10.1097/MPA.0000000000000389
10.1038/s41419-017-0052-1
10.18632/oncotarget.7168
10.1016/j.biopha.2017.11.113
10.2174/187152011795677463
10.1186/s12943-017-0588-9
10.4238/gmr15048936
10.1177/1533034616665720
ContentType Journal Article
Copyright 2019 Wiley Periodicals, Inc.
Copyright_xml – notice: 2019 Wiley Periodicals, Inc.
DBID AAYXX
CITATION
NPM
7TK
7U7
8FD
C1K
FR3
K9.
P64
RC3
7X8
DOI 10.1002/jcp.28188
DatabaseName CrossRef
PubMed
Neurosciences Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Genetics Abstracts
Technology Research Database
Toxicology Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList PubMed
Genetics Abstracts
CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Biology
EISSN 1097-4652
EndPage 15419
ExternalDocumentID 30693518
10_1002_jcp_28188
JCP28188
Genre article
Journal Article
GroupedDBID ---
-DZ
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
36B
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
85S
8UM
930
9M8
A03
AAESR
AAEVG
AAHHS
AAHQN
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDPE
ABEFU
ABEML
ABIJN
ABJNI
ABPPZ
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACNCT
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIAGR
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BQCPF
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMB
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
H~9
IH2
IX1
J0M
JPC
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M56
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MVM
MXFUL
MXSTM
N04
N05
N9A
NEJ
NF~
NNB
O66
O9-
OHT
OIG
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
ROL
RWI
RWR
RX1
RYL
S10
SAMSI
SUPJJ
SV3
TN5
TWZ
UB1
UPT
V2E
V8K
VQP
W8V
W99
WBKPD
WH7
WIB
WIH
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WXSBR
WYB
WYISQ
X7M
XG1
XJT
XOL
XPP
XSW
XV2
Y6R
YQT
YZZ
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
ADXHL
AETEA
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
NPM
PKN
7TK
7U7
8FD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
C1K
FR3
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c2688-452450f161ca3f86bb1e833a57a03c1e4e2f967f93792f53ffea618951604b0f3
IEDL.DBID DR2
ISSN 0021-9541
1097-4652
IngestDate Fri Jul 11 11:05:53 EDT 2025
Fri Jul 25 19:51:11 EDT 2025
Wed Feb 19 02:25:45 EST 2025
Thu Apr 24 23:06:46 EDT 2025
Tue Jul 01 01:32:00 EDT 2025
Wed Jan 22 16:38:31 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords miR-142/HIF-1α
pancreatic cancer
FEZF1-AS1
invasion
miR-133a/EGFR
Language English
License 2019 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2688-452450f161ca3f86bb1e833a57a03c1e4e2f967f93792f53ffea618951604b0f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-2444-5138
PMID 30693518
PQID 2229848518
PQPubID 1006363
PageCount 13
ParticipantIDs proquest_miscellaneous_2179446033
proquest_journals_2229848518
pubmed_primary_30693518
crossref_citationtrail_10_1002_jcp_28188
crossref_primary_10_1002_jcp_28188
wiley_primary_10_1002_jcp_28188_JCP28188
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2019
2019-09-00
2019-Sep
20190901
PublicationDateYYYYMMDD 2019-09-01
PublicationDate_xml – month: 09
  year: 2019
  text: September 2019
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Journal of cellular physiology
PublicationTitleAlternate J Cell Physiol
PublicationYear 2019
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References e_1_2_7_1_10_1
e_1_2_7_1_11_1
e_1_2_7_1_12_1
e_1_2_7_1_13_1
e_1_2_7_1_30_1
e_1_2_7_1_5_1
Wei H. (e_1_2_7_1_24_1) 2013; 17
e_1_2_7_1_29_1
e_1_2_7_1_6_1
Shibaji T. (e_1_2_7_1_18_1) 2003; 23
Erickson L. A. (e_1_2_7_1_7_1) 2015; 9
e_1_2_7_1_8_1
e_1_2_7_1_25_1
e_1_2_7_1_2_1
e_1_2_7_1_26_1
e_1_2_7_1_3_1
e_1_2_7_1_27_1
e_1_2_7_1_4_1
e_1_2_7_1_28_1
e_1_2_7_1_21_1
e_1_2_7_1_22_1
e_1_2_7_1_23_1
e_1_2_7_1_9_1
e_1_2_7_1_20_1
e_1_2_7_1_19_1
e_1_2_7_1_14_1
e_1_2_7_1_15_1
e_1_2_7_1_16_1
e_1_2_7_1_17_1
References_xml – ident: e_1_2_7_1_13_1
  doi: 10.3892/mmr.2015.3144
– volume: 9
  start-page: 2029
  year: 2015
  ident: e_1_2_7_1_7_1
  article-title: Targeting the hypoxia pathway to treat pancreatic cancer
  publication-title: Drug Design, Development and Therapy
– volume: 17
  start-page: 436
  issue: 4
  year: 2013
  ident: e_1_2_7_1_24_1
  article-title: Effects of the silencing of hypoxia‐inducible factor‐1 alpha on metastasis of pancreatic cancer
  publication-title: European Review for Medical and Pharmacological Sciences
– ident: e_1_2_7_1_3_1
  doi: 10.1038/onc.2015.325
– ident: e_1_2_7_1_23_1
  doi: 10.1089/ars.2007.1628
– ident: e_1_2_7_1_21_1
  doi: 10.18632/oncotarget.8834
– ident: e_1_2_7_1_25_1
  doi: 10.1002/jcb.25988
– ident: e_1_2_7_1_27_1
  doi: 10.2478/s11658-014-0212-6
– ident: e_1_2_7_1_22_1
  doi: 10.1016/j.bbrc.2011.04.035
– ident: e_1_2_7_1_28_1
  doi: 10.3892/ol.2013.1620
– ident: e_1_2_7_1_9_1
  doi: 10.1093/ije/dyx232
– ident: e_1_2_7_1_15_1
  doi: 10.1007/978-1-4939-3378-5_21
– ident: e_1_2_7_1_17_1
  doi: 10.1016/j.cell.2011.07.014
– ident: e_1_2_7_1_10_1
  doi: 10.1016/j.biopha.2017.08.057
– ident: e_1_2_7_1_20_1
  doi: 10.1177/1535370214555665
– ident: e_1_2_7_1_6_1
  doi: 10.1007/s11010-013-1795-3
– ident: e_1_2_7_1_8_1
  doi: 10.1586/17474124.2016.1117386
– ident: e_1_2_7_1_11_1
  doi: 10.1016/S0360-3016(00)00803-8
– ident: e_1_2_7_1_14_1
  doi: 10.1242/bio.021774
– ident: e_1_2_7_1_5_1
  doi: 10.1016/j.ctrv.2017.08.007
– ident: e_1_2_7_1_16_1
  doi: 10.1097/MPA.0000000000000389
– ident: e_1_2_7_1_29_1
  doi: 10.1038/s41419-017-0052-1
– ident: e_1_2_7_1_4_1
  doi: 10.18632/oncotarget.7168
– ident: e_1_2_7_1_26_1
  doi: 10.1016/j.biopha.2017.11.113
– volume: 23
  start-page: 4721
  issue: 6
  year: 2003
  ident: e_1_2_7_1_18_1
  article-title: Prognostic significance of HIF‐1 alpha overexpression in human pancreatic cancer
  publication-title: Anticancer Research
– ident: e_1_2_7_1_2_1
  doi: 10.2174/187152011795677463
– ident: e_1_2_7_1_12_1
  doi: 10.1186/s12943-017-0588-9
– ident: e_1_2_7_1_19_1
  doi: 10.4238/gmr15048936
– ident: e_1_2_7_1_30_1
  doi: 10.1177/1533034616665720
SSID ssj0009933
Score 2.4485993
Snippet Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment‐resistant phenotype induced by the extent of...
Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment-resistant phenotype induced by the extent of...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 15407
SubjectTerms Biotechnology
Cancer
Cell growth
Cell proliferation
Epidermal growth factor receptors
FEZF1‐AS1
Hypoxia
invasion
Invasiveness
Kinases
miR‐133a/EGFR
miR‐142/HIF‐1α
Pancreatic cancer
Phenotypes
Ribonucleic acid
RNA
Signal transduction
Tumors
Vascular endothelial growth factor
Title Long noncoding RNA FEZF1‐AS1 predicts poor prognosis and modulates pancreatic cancer cell proliferation and invasion through miR‐142/HIF‐1α and miR‐133a/EGFR upon hypoxia/normoxia
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.28188
https://www.ncbi.nlm.nih.gov/pubmed/30693518
https://www.proquest.com/docview/2229848518
https://www.proquest.com/docview/2179446033
Volume 234
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ditQwFA7LguCNP7v-jK4SRWRvOtMmaafFq2GZOi66yOjCIkJJMomO7rRlOiOOVz6Cr-K9z-BD-CSek_4s6w-Id6E5aZr0nORLcvIdQh4Ywy0MedKL_ER6QiXcU4xJj5kkYZLB-sfiReFnR9HkWByehCdb5FF7F6bmh-g23NAy3HiNBi5VNTgjDX2nyz5SGeFFX_TVQkA0PaOOSpow8s4FIRRByyrks0FX8vxc9BvAPI9X3YSTXiav20-t_Uze99cr1deffmFx_M-2XCGXGiBKR7XmXCVbJt8hu6McFuGLDX1InWuo23PfIRfqiJWbXfLtaZG_oXmR6wInPTo9GtF0_CoNfnz-MnoR0HKJBz-ripZFsaTo_JUX1byiMp_RRTHDWGEGMkHVHFjVVKPWLSmeH6D4KXraOGVxReb5B4nbebQJJ0QX8ynUFAg2mDxJMfX9a_3u-jnncjB-nE7puoRCbzdl8XEuBzngckxcI8fp-OXBxGsCQHiaRWDBImQi9C2AUi25jSOlAhPDm8Kh9LkOjDDMJtHQAsRKmA25tUZGQQygMfKF8i2_TrahR8xNAq1JAiutsXzGhQmFEmJoIyW0igFzCdMj-60qZLphR8cgHadZzevMMvhHmftHPXK_Ey1rSpA_Ce21-pQ1o0KVYez0WADGhex7XTbYM3ayzE2xBhkcIUXkc94jN2o97GqB5V3CXel9p01_rz47PHjuErf-XfQ2uQhosHGg2yPbq-Xa3AHEtVJ3nWn9BNjwK2U
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELVKEaIvXFouCwUMQqgv2SS2k00kXlZlw7ZsV2hppQoJRU7WLgvdJNoLYnniE_gV3vkGPoIvYca5VOUiId6seGzH8Yx9bE_OEPJYKa5hypOW74TSEknIrYQxaTEVhkwy2P9o_FH4YOj3j8T-sXe8Rp7W_8KU_BDNgRtahpmv0cDxQNo-Yw19lxZt5DIKLpCLGNEbmfOfjc7Io8IqkLxxQvCEW_MKOcxuip5fjX6DmOcRq1lyoqvkTf2ypafJ-_ZykbTTT7_wOP5vb66RKxUWpd1Sea6TNZVtkq1uBvvw6Yo-ocY71By7b5JLZdDK1Rb5NsizE5rlWZrjukdHwy6Neq8j98fnL91XLi1mePezmNMiz2cU_b-yfD6ZU5mN6TQfY7gwBZmgbQavpjRFxZtRvEJA8VN0tjH6YopMsg8ST_RoFVGITicjaMkVzO7vRZj6_rWsu3zOubR7z6MRXRZQ6O2qyD9OpJ0BNMfEDXIU9Q53-1YVA8JKmQ9GLDwmPEcDLk0l14GfJK4KoCavIx2eukoopkO_owFlhUx7XGslfTcA3Og7InE0v0nW4Yuo2wR6E7paaqX5mAvliUSIjvYTkSYBwC6hWmSn1oU4rQjSMU7HaVxSO7MYxig2Y9QijxrRomQF-ZPQdq1QcTUxzGMMnx4IgLmQ_bDJBpPGjywzlS9BBidJ4Tuct8itUhGbVmCHF3JTeseo09-bj_d3X5rEnX8XfUAu9w8PBvFgb_jiLtkAcFj5022T9cVsqe4BAFsk942d_QRkYC-B
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLVKEYgNj5bHQAGDEOomk8R2MolYjdoJ01JG1UClCiFFtseGgY4TzQMxrPgEfoU938BH8CVcO8lU5SEhdlZ8Hedxrn3s3JyL0COlqIYhj3txkHKPiZR6ghDuEZWmhBNY_2j7o_DzQdw_YvvH0fEaetL8C1PpQ6w23KxnuPHaOng50v6paOg7WbatlFFyDp1n0JPN27A7PNWOSus88i4GIWJhIysUEH_V9Oxk9BvDPEtY3YyTXUGvm2utAk3etxdz0ZaffpFx_M-buYou10wUdyvoXENrymygza6BVfhkiR9jFxvqNt030IUqZeVyE307KMwbbAojCzvr4eGgi7Peqyz88flL90WIy6n98jOf4bIopthGf5liNp5hbkZ4UoxssjAFlYA1x1YllhZ2U2w_IFjzExtq49DimozNB27383CdTwhPxkPoKWTE7-9ltvT9a3Xu6jil3O89zYZ4UUKjt8uy-DjmvgFibgvX0VHWe7nT9-oMEJ4kMbgwiwiLAg2sVHKqk1iIUCVwpqjDAypDxRTRadzRwLFSoiOqteJxmABrjAMmAk1voHV4IuoWgrtJQ8210nREmYqYYKyjY8GkSIB0MdVC2w0UclnLo9ssHSd5JexMcnhHuXtHLfRwZVpWmiB_Mtpq8JTXw8Ist8nTEwYkF6ofrKrBoe1D5kYVC7CxQyQAmtIWulnhcNULrO9S6lpvOzT9vft8f-fQFW7_u-l9dPFwN8sP9gbP7qBLwAzrYLottD6fLtRdYF9zcc952U-_ZC4w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long+noncoding+RNA+FEZF1%E2%80%90AS1+predicts+poor+prognosis+and+modulates+pancreatic+cancer+cell+proliferation+and+invasion+through+miR%E2%80%90142%2FHIF%E2%80%901%CE%B1+and+miR%E2%80%90133a%2FEGFR+upon+hypoxia%2Fnormoxia&rft.jtitle=Journal+of+cellular+physiology&rft.au=Ou%2C+Zheng%E2%80%90Lin&rft.au=Zhang%2C+Min&rft.au=Ji%2C+Lian%E2%80%90Dong&rft.au=Luo%2C+Zhen&rft.date=2019-09-01&rft.issn=0021-9541&rft.eissn=1097-4652&rft.volume=234&rft.issue=9&rft.spage=15407&rft.epage=15419&rft_id=info:doi/10.1002%2Fjcp.28188&rft.externalDBID=10.1002%252Fjcp.28188&rft.externalDocID=JCP28188
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon